Research Progress and Application of Daratumumab in Non-Multiple Myeloma--Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 1574-1578, 2023.
Article
in Chinese
| WPRIM
| ID: wpr-1010008
ABSTRACT
Daratumumab is the first CD38 monoclonal antibody drug approved for the treatment of patients with multiple myeloma. It can bind to CD38 expressed by tumor cells, inhibit tumor cell growth and induce myeloma cell apoptosis through a variety of immune-related mechanisms. Meanwhile, CD38 is also expressed in other cells, including regulatory T cells, regulatory B cells and myeloid-derived suppressor cells, which provides a theoretical basis for the treatment of hematological tumor diseases other than non-multiple myeloma diseases. This article reviews the research progress and application of this part.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Hematologic Neoplasms
/
ADP-ribosyl Cyclase 1
/
Antibodies, Monoclonal
/
Multiple Myeloma
Limits:
Humans
Language:
Chinese
Journal:
Journal of Experimental Hematology
Year:
2023
Type:
Article
Similar
MEDLINE
...
LILACS
LIS